Transcriptomic changes induced by mycophenolic acid in gastric cancer cells

American Journal of Translational Research

Volumn 6, Issue 1, 2014, Pages 28-42

  Dun, Boying ^a,b,c   Sharma, Ashok ^b   Xu, Heng ^a,b   Liu, Haitao ^b   Bai, Shan ^b   Zeng, Lingwen ^c   She, Jin Xiong ^a,b  

^a NANJING TECH UNIVERSITY   (China)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

Author keywords

Drug repurposing; Microarray; MPA; Regulatory networks

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; AURORA A KINASE; AURORA B KINASE; BUB1 RELATED PROTEIN; CELL CYCLE PROTEIN 20; CYCLIN A2; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN E; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FAS ANTIGEN; MYCOPHENOLIC ACID; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; RIBONUCLEOTIDE REDUCTASE; SMAD3 PROTEIN; THIOREDOXIN INTERACTING PROTEIN; TRANSCRIPTION FACTOR E2F7; TRANSCRIPTOME;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPECTROPHOTOMETRY; STOMACH CANCER; WESTERN BLOTTING;

EID: 84889689705     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Morath C, Schwenger V, Beimler J, Mehrabi A, Schmidt J, Zeier M and Muranyi W. Antifibrotic actions of mycophenolic acid. Clin Transplant 2006; 20 Suppl 17: 25-29.
2. Allison AC and Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
3. Jackson RC, Weber G and Morris HP. IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature 1975; 256: 331-333.
4. Fellenberg J, Bernd L, Delling G, Witte D and Zahlten-Hinguranage A. Prognostic significance of drug-regulated genes in high-grade osteosarcoma. Mod Pathol 2007; 20: 1085-1094.
5. Fellenberg J, Kunz P, Sahr H and Depeweg D. Overexpression of inosine 5'-monophosphate dehydrogenase type II mediates chemoresistance to human osteosarcoma cells. PLoS One 2010; 5: e12179.
6. Millan O, Oppenheimer F, Brunet M, Vilardell J, Rojo I, Vives J and Martorell J. Assessment of mycophenolic acid-induced immunosuppression: a new approach. Clin Chem 2000; 46: 1376-1383.
7. Allison AC and Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005; 80: S181-190.
8. Takebe N, Cheng XF, Fandy TE, Srivastava RK, Wu SL, Shankar S, Bauer K, Shaughnessy J and Tricot G. IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells. Mol Cancer Ther 2006; 5: 457-466.
9. Gortz A, Franklin TJ, Dive C and Hickman JA. Cell cycle specific induction of HL-60 cell differentiation and apoptosis by mycophenolic acid. Cell Death Differ 1997; 4: 787-795.
10. Vegso G, Sebestyen A, Paku S, Barna G, Hajdu M, Toth M, Jaray J and Kopper L. Antiproliferative and apoptotic effects of mycophenolic acid in human B-cell non-Hodgkin lymphomas. Leuk Res 2007; 31: 1003-1008.
11. Silva SL, Silva SF, Cavalcante RO, Mota RS, Carvalho RA, Moraes MO, Campos HH and Moraes ME. Mycophenolate mofetil attenuates Walker's tumor growth when used alone, but the effect is lost when associated with cyclosporine. Transplant Proc 2004; 36: 1004-1006.
12. Domhan S, Muschal S, Schwager C, Morath C, Wirkner U, Ansorge W, Maercker C, Zeier M, Huber PE and Abdollahi A. Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid. Mol Cancer Ther 2008; 7: 1656-1668.
13. Tressler RJ, Garvin LJ and Slate DL. Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo. Int J Cancer 1994; 57: 568-573.
14. Dun B, Xu H, Sharma A, Liu H, Yu H, Yi B, Liu X, He M, Zeng L and She JX. Delineation of biological and molecular mechanisms underlying the anticancer activities of mycophenolic acid. Int J Clin Exp Pathol 2013; [Epub ahead of print].
15. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: Article3.
16. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B 1995; 57: 289-300.
17. Sharma A, Podolsky R, Zhao J and McIndoe RA. A modified hyperplane clustering algorithm allows for efficient and accurate clustering of extremely large datasets. Bioinformatics 2009; 25: 1152-1157.
18. Falcon S and Gentleman R. Using GOstats to test gene lists for GO term association. Bioinformatics 2007; 23: 257-258.
19. Tarca AL, Draghici S, Khatri P, Hassan SS, Mittal P,Kim JS, Kim CJ, Kusanovic JP and xRomero/x R. A novel signaling pathway impact analysis. Bioinformatics 2009; 25: 75-82.
20. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C and Jensen LJ. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 2013; 41: D808-815.
21. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498-2504.
22. Nigg EA. Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. Bioessays 1995; 17: 471-480.
23. Ortonne JP. Redefining clinical response in psoriasis: targeting the pathological basis of disease. J Drugs Dermatol 2004; 3: 13-20.
24. Wierstra I and Alves J. FOXM1, a typical proliferation-associated transcription factor. Biol Chem 2007; 388: 1257-1274.
25. Laoukili J, Kooistra MR, Bras A, Kauw J, Kerkhoven RM, Morrison A, Clevers H and Medema RH. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 2005; 7: 126-136.
26. Kim J, Goo SY, Chung HJ, Yang HW, Yong TS, Lee KH and Park SJ. Interaction of beta-giardin with the Bop1 protein in Giardia lamblia. Parasitol Res 2006; 98: 138-144.
27. Seillier M, Peuget S, Gayet O, Gauthier C, N'Guessan P, Monte M, Carrier A, Iovanna JL and Dusetti NJ. TP53INP1, a tumor suppressor, interacts with LC3 and ATG8-family proteins through the LC3-interacting region (LIR) and promotes autophagy-dependent cell death. Cell Death Differ 2012; 19: 1525-153
28. Lerner AG, Upton JP, Praveen PV, Ghosh R, Nakagawa Y, Igbaria A, Shen S, Nguyen V, Backes BJ, Heiman M, Heintz N, Greengard P, Hui S, Tang Q, Trusina A, Oakes SA and Papa FR. IRE1alpha induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress. Cell Metab 2012; 16: 250-264.
29. Gonzalez R, Ferrin G, Aguilar-Melero P, Ranchal I, Linares CI, Bello RI, De la Mata M, Gogvadze V, Barcena JA, Alamo JM, Orrenius S, Padillo FJ, Zhivotovsky B and Muntane J. Targeting hepatoma using nitric oxide donor strategies. Antioxid Redox Signal 2013; 18: 491-506.
30. Zeng Y, He Y, Yang F, Mooney SM, Getzenberg RH, Orban J and Kulkarni P. The cancer/testis antigen prostate-associated gene 4 (PAGE4) is a highly intrinsically disordered protein. J Biol Chem 2011; 286: 13985-13994.
31. Morgensztern D and McLeod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 2005; 16: 797-803.
32. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS and Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 2008; 8: 393-412.
33. Cortot A, Armand JP and Soria JC. [PI3K-AKT-mTOR pathway inhibitors]. Bull Cancer 2006; 93: 19-26.
34. Wajant H. The Fas signaling pathway: more than a paradigm. Science 2002; 296: 1635-1636.
35. Huang B, Eberstadt M, Olejniczak ET, Meadows RP and Fesik SW. NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain. Nature 1996; 384: 638-641.